Biotechnology News

Browse the latest Biotechnology news. Use the menu or navigation tiles to change industry or topic.

January 23, 2026 17:25 ET | Source: Immunovant Inc.

Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

DURHAM, N.C. and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the third quarter ended December 31, 2025, and...
January 23, 2026 16:05 ET | Source: TELA Bio, Inc.

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., Jan. 23, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction...
January 23, 2026 16:01 ET | Source: Erasca, Inc.

Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN DIEGO, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
January 23, 2026 16:00 ET | Source: Spyre Therapeutics, Inc.

Spyre Therapeutics Announces Grants of Inducement Awards

WALTHAM, Mass., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and...
January 23, 2026 08:00 ET | Source: Adagene Inc.

Adagene Provides Business Update and 2026 Objectives

Data update from the ongoing Phase 1b/2 study of muzastotug + pembrolizumab in 3L+ MSS CRC patients remains on track for Q1 2026 Unaudited cash and cash equivalents of $74.5 million as of December...
January 23, 2026 08:00 ET | Source: Ocugen

Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock

MALVERN, Pa., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of its previously...
January 23, 2026 07:30 ET | Source: Sanara MedTech Inc.

Sanara MedTech Inc. Reports Unaudited Preliminary Financial Results for the Fourth Quarter and Full Year 2025; Introduces Full Year 2026 Financial Guidance

FORT WORTH, TX, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara MedTech,” “Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on...
January 23, 2026 07:00 ET | Source: NextCure

NextCure Provides Business Update

SIM0505 (CDH6 ADC) Phase 1 dose escalation data update anticipated in Q2 2026LNCB74 (B7-H4 ADC) Phase 1 dose escalation expanded into higher dose cohorts BELTSVILLE, Md., Jan. 23, 2026 (GLOBE...
January 23, 2026 02:00 ET | Source: Bavarian Nordic A/S

Bavarian Nordic indgår distributionsaftale med Eurofarma for at udvide adgangen til chikungunya-vacciner i Brasilien

Aftalen muliggør den første markedslancering i Latinamerika for Bavarian Nordics chikungunya‑vaccineRummer mulighed for udvidelse til at dække resten af Latinamerika KØBENHAVN, Danmark, 23. januar...
January 23, 2026 02:00 ET | Source: Bavarian Nordic A/S

Bavarian Nordic Signs Distribution Agreement with Eurofarma to Expand Access to Chikungunya Vaccine in Brazil

Bavarian Nordic has signed a distribution agreement with Eurofarma for its chikungunya vaccine in Brazil with potential to expand to rest of Latin America